Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications
Abstract
Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic fatty liver disease, is a highly prevalent metabolic liver disorder, closely linked to obesity, insulin resistance, and chronic low-grade inflammation. While traditionally viewed through the liver-adipose-gut axes, emerging evidence identifies the liver-spleen axis as a critical pathway in disease progression. This review examines the anatomical and portal vascular connections that facilitate direct communication between these organs, focusing on how splenic immune reprogramming—specifically involving myeloid-derived suppressor cells, natural killer/natural killer T cells, and pro-inflammatory signaling—drives the transition from simple steatosis to advanced cirrhosis. We further explore the diagnostic utility of splenic volume, metabolic activity, and stiffness as non-invasive markers that correlate with the severity of hepatic fibrosis and portal hypertension. In conclusion, the spleen serves as a vital immunometabolic regulatory hub and a sentinel for hepatic stress. Recognizing this axis offers significant potential for precision diagnostics and novel therapeutic interventions. Future research should focus on longitudinal intervention trials and multi-omics studies to fully decode the signaling crosstalk within the NAFLD spectrum, shifting the management of the disease toward a more systemic, integrated approach.
Related
- Crosstalk mechanisms, clinical correlations and therapeutic implications linking OSA with HFpEF progression
- Gut Microbiota-Driven Neuroimmune Crosstalk in Ulcerative Colitis: From Mechanisms to Therapeutic Implications
- MicroRNA-mediated crosstalk between Wnt/β-catenin signaling and the NLRP3 inflammasome in breast cancer: mechanistic evidence and therapeutic implications
- Insulin resistance and oxidative stress: Two therapeutic targets in non-alcoholic steatohepatitis
- Deciphering the Therapeutic Effect of Quercetin-Loaded Pumpkin Seed Oil Nanoemulsion on Rheumatoid Arthritis in a Rat Model
BibTeX
@article{tarantino2026liverspleen,
title = {{Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications}},
author = {Giovanni Tarantino and Vincenzo Citro},
journal = {World Journal of Gastroenterology},
year = {2026},
month = jun,
doi = {10.3748/wjg.119467},
url = {https://doi.org/10.3748/wjg.119467},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Liver-spleen axis: Deciphering a crucial crosstalk in non-alcoholic fatty liver disease progression and therapeutic implications
AU - Giovanni Tarantino
AU - Vincenzo Citro
PY - 2026
DA - 2026/06/02
JO - World Journal of Gastroenterology
DO - 10.3748/wjg.119467
UR - https://doi.org/10.3748/wjg.119467
AB - Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic fatty liver disease, is a highly prevalent metabolic liver disorder, closely linked to obesity, insulin resistance, and chronic low-grade inflammation. While traditionally viewed through the liver-adipose-gut axes, emerging evidence identifies the liver-spleen axis as a critical pathway in disease progression. This review examines the anatomical and portal vascular connections that facilitate direct communication between these organs, focusing on how splenic immune reprogramming—specifically involving myeloid-derived suppressor cells, natural killer/natural killer T cells, and pro-inflammatory signaling—drives the transition from simple steatosis to advanced cirrhosis. We further explore the diagnostic utility of splenic volume, metabolic activity, and stiffness as non-invasive markers that correlate with the severity of hepatic fibrosis and portal hypertension. In conclusion, the spleen serves as a vital immunometabolic regulatory hub and a sentinel for hepatic stress. Recognizing this axis offers significant potential for precision diagnostics and novel therapeutic interventions. Future research should focus on longitudinal intervention trials and multi-omics studies to fully decode the signaling crosstalk within the NAFLD spectrum, shifting the management of the disease toward a more systemic, integrated approach.
SN - 1007-9327
SN - 2219-2840
ER -